Provided by Tiger Fintech (Singapore) Pte. Ltd.

Revolution Medicines, Inc.

40.67
-0.8000-1.93%
Post-market: 40.56-0.1100-0.27%19:15 EDT
Volume:3.04M
Turnover:123.67M
Market Cap:7.56B
PE:-11.37
High:41.72
Open:41.31
Low:40.20
Close:41.47
Loading ...

Revolution Medicines Inc (RVMD) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ...

GuruFocus.com
·
27 Feb

U.S. RESEARCH ROUNDUP-Abbvie, Freeport-McMoran, Goldman Sachs

Reuters
·
27 Feb

Revolution Medicines Inc : Leerink Partners Cuts Target Price to $62 From $65

THOMSON REUTERS
·
27 Feb

Revolution Medicines Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
27 Feb

Revolution Medicines Q4 Net Loss Narrows

MT Newswires Live
·
27 Feb

Revolution Medicines Q4 2024 GAAP EPS $(1.12) Misses $(1.00) Estimate

Benzinga
·
27 Feb

Earnings Flash (RVMD) Revolution Medicines Q4 Loss of $1.12 per Share vs. FactSet Est Loss of $0.99

MT Newswires Live
·
27 Feb

BRIEF-Revolution Medicines Q4 EPS USD -1.12

Reuters
·
27 Feb

Revolution Medicines Q4 EPS USD -1.12

THOMSON REUTERS
·
27 Feb

Revolution Medicines Reports Fourth Quarter and Full Year 2024 Financial Results and Update on Corporate Progress

GlobeNewswire
·
27 Feb

Revolution Medicines to Participate in March 2025 Investor Conferences

GlobeNewswire
·
25 Feb

Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2024 After Market Close on February 26, 2025

GlobeNewswire
·
20 Feb

Revolution Medicines to Participate in the Guggenheim Securities SMID Cap Biotech Conference

GlobeNewswire
·
30 Jan

Keros Therapeutics (KROS) Soars 5.1%: Is Further Upside Left in the Stock?

Zacks
·
22 Jan

Revolution Medicines (RVMD) Receives a Buy from Barclays

TIPRANKS
·
22 Jan

S&P 500 Futures Climb In Premarket Trading; JB Hunt Transport, Bruker Corp Lag

Dow Jones
·
17 Jan

Barclays Reaffirms Their Buy Rating on Revolution Medicines (RVMD)

TIPRANKS
·
16 Jan

Analysts’ Top Healthcare Picks: Envista Holdings (NVST), Revolution Medicines (RVMD)

TIPRANKS
·
12 Jan

Revolution Medicines Is Maintained at Buy by UBS

Dow Jones
·
08 Jan

UBS Adjusts Price Target on Revolution Medicines to $71 From $65, Keeps Buy Rating

MT Newswires Live
·
08 Jan